California-based SanBio has appointed Dr Jay Stout as senior vice president of manufacturing.
In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development.
Dr Stout said: “I’m eager to roll up my sleeves to prepare SanBio’s promising cell therapies for scaled-up production and rapid rollout.
“The clinical results are exciting and brings a breakthrough technology to commercialisation is a challenge I’ve met several times before.”
He brings 25 years of biological development and commercialisation expertise to SanBio, having most recently served as executive director of Merck’s Center for Biopharmaceutical Manufacturing.
Prior to this, Dr Stout was executive director of Amgen’s Manufacturing Sciences and Technology group during which time he served as global process team lead of its blockbuster anti-TBF product, Enbrel.
Keita Mori, SanBio’s chief executive officer, said: “We’re delighted to welcome Jay on board.
“He is perhaps the individual with the greatest experience in the world in manufacturing scale-up of biologics similar to SB623 stem cell therapy.
“He fills our what is a genuinely world-class development and operations team.”